Showing results (11-20 of 42) with videos related to
Sort By:
Pageof 5
Journal of the European Academy of Dermatology and Venereology : JEADV|August 19, 2016
Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trialsD Thaçi, A Kimball, P Foley, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 16, 2014
Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapyB E Strober, Y Poulin, C Teller, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 25, 2013
Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACHY Poulin, J J Crowley, R G Langley, et al.The British Journal of Dermatology|October 17, 2015
Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0·015% gel: a randomized, controlled 12-month studyC Garbe, N Basset-Seguin, Y Poulin, et al.The British Journal of Dermatology|June 29, 2020
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trialR B Warren, A Blauvelt, Y Poulin, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|April 28, 2011
Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trialsL Guenther, C Han, P Szapary, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|October 29, 2011
Cost-effectiveness evaluation of clobetasol propionate shampoo (CPS) maintenance in patients with moderate scalp psoriasis: a Pan-European analysisK Papp, Y Poulin, K Barber, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2020
Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasisY Poulin, M Ramon, L Rosoph, et al.Journal of Drugs in Dermatology : JDD|December 31, 2008
Etanercept in the treatment of palmoplantar pustulosisR Bissonnette, Y Poulin, C Bolduc, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 7, 2017
Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patientsM Masson Regnault, M-P Konstantinou, A Khemis, et al.Pageof 5